组织工程与重建外科杂志

组织工程与重建外科杂志 ›› 2019, Vol. 15 ›› Issue (4): 263-265.doi: 10.3969/j.issn.1673-0364.2019.04.012

• 综述 • 上一篇    下一篇

西罗莫司治疗脉管畸形的研究进展

孙步豪，沈卫民   

  1. 南京医科大学附属儿童医院烧伤整形外科
  • 收稿日期:2019-03-07 修回日期:2019-04-23 出版日期:2019-08-20 发布日期:2019-08-20
  • 作者简介:沈卫民(E-mail:swmswmswm@sina.com)。

Advances of Sirolimus in the Treatment of Vascular Malformation

SUN Buhao   

  • Received:2019-03-07 Revised:2019-04-23 Online:2019-08-20 Published:2019-08-20

摘要： 脉管畸形是一组起源于血管和(或)淋巴管的发育畸形,可侵袭多个脏器和系统,造成疼痛、毁容、功能障碍,甚至危及生命。目前,脉管畸形的治疗方法多样,但效果不尽如人意。西罗莫司是哺乳动物雷帕霉素靶蛋白受体抑制剂,治疗脉管畸形效果较好。本文对西罗莫司治疗脉管畸形疾病的机制、应用效果及可能的副作用进行综述。

关键词: 西罗莫司, 脉管畸形, 有效性, 安全性

Abstract: Vascular malformation is a group of developmental malformations originating from blood vessels and/or lymphatics that can invade multiple organs and systems, causing pain, disfigurement, dysfunction, and even death. At present, the treatment methods of vascular malformation are various, but the effect is not satisfactory. Sirolimus, a mammalian target protein receptor inhibitor of rapamycin, has been shown to be effective in the treatment of vascular malformations. In this paper, the mechanism, application, effect and possible side effects of sirolimus in treating vascular malformation were reviewed, in order to provide a new idea for treating such diseases.

Key words: Sirolimus, Vascular malformation, Effectiveness, Safety

中图分类号: